Investigating the effect of empagliflozin and melijent in chronic kidney failure patients
Phase 1
Recruiting
- Conditions
- Diabetic patients.Type 2 diabetes mellitus with kidney complicationsE11.2
- Registration Number
- IRCT20230607058409N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Patients with over 20mL/min/1.73m2 (calculated by MDRD formula) in the first visit
Patient over 18 years old patients
-Patients with less 60 ml /min/1.73m2 (calculated by MDRD formula) in the first visit
Exclusion Criteria
Class four congestive heart failure
Recurrent urinary infection
Myocardial infarction, stroke, transient ischemic attack
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Examination of renal function (GFR). Timepoint: The effect of improving the renal function of GFR at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: 140-Age*weight/ creatinine plasma*72.;The amount of proteinuria. Timepoint: The amount of proteinuria at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: 24-hour proteinuria (mg/dl).
- Secondary Outcome Measures
Name Time Method Blood pressure. Timepoint: Blood pressure at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: Mercury pressure gauge.;Fasting sugar. Timepoint: Fasting blood sugar levels at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: Fasting blood sugar test (mg/dl).